Pfizer Net Tangible Assets from 2010 to 2026
| PFE Stock | USD 27.22 0.73 2.76% |
Net Tangible Assets | First Reported 2009-06-30 | Previous Quarter 6 B | Current Value 5.2 B | Quarterly Volatility 24.3 B |
Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 B, Interest Expense of 2.8 B or Total Revenue of 40.3 B, as well as many indicators such as Price To Sales Ratio of 4.38, Dividend Yield of 0.0725 or PTB Ratio of 1.44. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.
Pfizer | Net Tangible Assets | Build AI portfolio with Pfizer Stock |
Analyzing Pfizer's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing Pfizer's current valuation and future prospects.
Latest Pfizer's Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Pfizer Inc over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Pfizer's Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Pfizer Net Tangible Assets Regression Statistics
| Arithmetic Mean | 23,793,559,118 | |
| Geometric Mean | 34,404,915,569 | |
| Coefficient Of Variation | 243.64 | |
| Mean Deviation | 53,814,540,138 | |
| Median | (5,963,000,000) | |
| Standard Deviation | 57,970,956,234 | |
| Sample Variance | 3360631766.6T | |
| Range | 155.1B | |
| R-Value | 0.82 | |
| Mean Square Error | 1156316233.8T | |
| R-Squared | 0.68 | |
| Significance | 0.000049 | |
| Slope | 9,448,695,931 | |
| Total Sum of Squares | 53770108266.2T |
Pfizer Net Tangible Assets History
About Pfizer Financial Statements
Pfizer stakeholders use historical fundamental indicators, such as Pfizer's Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Pfizer investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pfizer's assets and liabilities are reflected in the revenues and expenses on Pfizer's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pfizer Inc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 102.4 B | 107.5 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out the analysis of Pfizer Correlation against competitors. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Will Pharmaceuticals sector continue expanding? Could Pfizer diversify its offerings? Factors like these will boost the valuation of Pfizer. Anticipated expansion of Pfizer directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pfizer data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.21) | Dividend Share 1.72 | Earnings Share 1.36 | Revenue Per Share | Quarterly Revenue Growth (0.01) |
Investors evaluate Pfizer Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Pfizer's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Pfizer's market price to deviate significantly from intrinsic value.
It's important to distinguish between Pfizer's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pfizer should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Pfizer's market price signifies the transaction level at which participants voluntarily complete trades.